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To determine the nature of the mechanism by which certain
derived ruthenium (Ru) complexes induce regression in tumour
growth, we have investigated the possibility that this mechanism
was associated with an increase of superoxide anion (O
#
−d)
production by phagocytic cells, which are usually found in
tumour nodes. Here we present evidence that a newly synthesized
complex, Ru$+–propylene-1,2-diaminotetra-acetic acid (Ru–
PDTA), derived from Ru and the sequestering ligand (PDTA),
specifically stimulates O
#
−d production. This increase was assoc-
iated with the translocation of cytosolic factors p47phox and
p67phox of NADPH oxidase to the plasma membrane. The
INTRODUCTION
The potential use of ruthenium (Ru$+) complexes in cancer
chemotherapy has been recognized by researchers in different
areas [1–4]. These substances have not only shown good anti
tumour activity in screening studies [5,6], but many also localize
in tumour tissues [7]. Ru$+ compounds, as prodrugs, can be
reduced in the hypoxic tumoural areas into more active species
which bind rapidly to cellular DNA [8,9]. In this way, amine–Ru
complexes may be activated in io to co-ordinate the appropriate
atoms of the nucleobase in a similar fashion to that of platinum
anticancer drugs [10–12]. A recently investigated new group of
promising anticancer compounds, namely Ru complexes with
polyaminopolycarboxylic chelating ligands, are highly soluble in
water and their active forms are six-co-ordinate with octahedral
structures [13]. Recently we synthesized and characterized a new
molecule formed by Ru$+ and the chelating ligand propylene-1,2-
diaminetetra-acetic acid (PDTA) [14]. Compounds formed by
this chelating agent, a methyl derivative of EDTA, are about two
orders of magnitude more stable than the analogues formed with
the parent ligand. It is likely that these complexes are transported
to the tumour site by transferrin [15,16]. Indeed, the in io
distribution of Ru might be determined by its interaction with
this iron-transport protein because of similarities between the
two metal ions. Since malignant cells have a high requirement for
iron, it has been suggested that the accumulation of Ru$+
complexes in tumour cells might be mediated by transferrin [8].
NADPH oxidase, an enzyme found in phagocytic cells,
catalyses the reduction of oxygen to O
#
−d using NADPH as the
electron donor (see for a review, 17-21). The O
#
−d that is formed,
along with reactive species derived from it, is used as a potent
Abbreviations used: [Ca2+]i, cytosolic free calcium concentration ; DPI, diphenylene iodonium; Ru–PDTA, complex from ruthenium (Ru
3+) and
propylene-1,2-diaminotetra-acetic acid ²PDTA, [Ru(C11H15N2O8)Cl2]H,4H2O´ ; O2−d, superoxide anion.
1 To whom correspondence should be addressed.
Ru–PDTA-complex-dependent O
#
−d production was abrogated
by staurosporine, partially inhibited by diphenylene iodonium,
and it was insensitive to pertussis toxin or dibutyryl cyclic AMP
pretreatment. An increase of cytosolic Ca#+ levels were also
detected in neutrophils treated with the Ru–PDTA complex.
Also, Ru–PDTA complex induced the phosphorylation of tyro-
sine residues of several proteins as assessed by Western blotting.
Present data are consistent with the possibility that Ru–PDTA-
dependent antitumour effects are due in part to the complex’s
ability to stimulate the release of toxic oxygen metabolites from
phagocytic cells infiltrating tumour masses.
antimicrobial weapon in the process of host defence. The
NADPH oxidase complex consists of two membrane-bound
redox centres : a FAD-containing flavoprotein and a hetero-
dimeric b-type cytochrome, cytochrome b
−#%&
(also called cyto-
chrome b
&&)
). The oxidase is dormant in resting neutrophils, but
acquires catalytic activity when the cells are exposed to ap-
propriate stimuli [22]. The components of NADPH oxidase exist
in the form of a complex that contains the cytosolic proteins
p47phox and p67phox. The fact that the O
#
−d-forming NADPH
oxidase is always recovered in the particulate fraction suggests
that, in the course of physiological enzyme activation, cytosolic
components are translocated to the membrane.
The present study was undertaken to analyse whether the
novel Ru–PDTA complex was able to activate the respiratory
burst in human neutrophils. This activity could be associated
with the cytostatic capacity of specific cells, such as neutrophils,
which participate in the defence mechanisms. It is known that
activated phagocytic cells have the capacity to exert cytotoxicity
towards tumour cells in itro. It is also known that phagocytic
cells infiltrate tumour nodes and that they are very proximal to
tumour cells [23]. The present paper provides evidence that the
Ru–PDTA complex stimulates O
#
−d production and also that it
increases cytoplasmic Ca#+ levels by human neutrophils in itro.
This effect could mediate the tumour regression that was observed
with the Ru–PDTA complex in previous studies [24].
EXPERIMENTAL
Materials
Ru–PDTA complex (molecular mass 548.3) was synthesized as
described previously [14]. Chemicals were of analytical grade
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from Merck (Darmstadt, Germany). Cytochrome c, Fura-2
acetoxymethyl ester, pertussis toxin, dibutyryl cyclic AMP and
horseradish peroxidase conjugated with goat anti-mouse IgG
were obtained from Sigma Chemical (Madrid, Spain). Other
biochemical reagents were from Boehringer (Mannheim,
Germany). 2-Mercaptoethanol, SDS, acrylamide, NN«-
methylenebisacrylamide, Coomassie Brilliant Blue R-250 and
nitrocellulose blotting membranes were purchased from Bio-Rad
(Richmond, CA, U.S.A.). Ficoll 400 and molecular-mass
standards were from Pharmacia (Uppsala, Sweden). Stauro-
sporine was purchased from Calbiochem–Boehringer (La Jolla,
CA, U.S.A.). Rabbit polyclonal antibodies raised against p47phox
and p67phox, together with diphenylene iodonium (DPI) were
kindly given by Professor O. T. G. Jones (Department of Bio-
chemistry, University of Bristol, Bristol, U.K.). Monoclonal
antibody specific for phosphotyrosine (PY20) was purchased
from Transduction Laboratories (Lexington, KY, U.S.A.).
Luminol (5-amino-2,3-dihydrophthalazine-1,4-dione) was pur-
chased from Serva (Spain) and 4-iodophenol was from Aldrich.
Neutrophil preparation and culture
Neutrophils were obtained from normal adult human subjects
and purified by dextran sedimentation and Ficol–Hypaque
centrifugation as indicated in [25]. Neutrophils (5¬10' cells}ml)
were suspended in Krebs–Ringer bicarbonate buffered with
Hepes (KRB), pH 7.4 (118 mM NaCl}4.75 mM KCl}1.18 mM
KH
#
PO
%
}1.18 mM MgSO
%
}10 mM Hepes}25 mM NaHCO
$
}
1.25 mM CaCl
#
) and containing 10 mM glucose. Further
additions are described in the legends to the individual Figures.
Preparation of cytosolic and membrane fractions
After different times of incubation cells were centrifuged (800 g)
and lysed in buffer A [100 mM Hepes (pH 7.3)}100 mM KCl}
3 mM NaCl}3 mM MgCl
#
}1.25 mM EGTA}1 mM PMSF}
5 lg}ml aprotinin}156 lg}ml benzamidine]. The cells were dis-
rupted by sonication on ice (20 W for three bursts of 5 s each,
separated by 30 s intervals). Unbroken cells and debris were
removed by centrifugation at 10000 g for 5 min at 4 °C. The
cytosolic fraction was obtained by ultracentrifugation at 92000 g
for 60 min at 4 °C, as indicated in [26]. The pellets were
resuspended in the sonication buffer B, with detergent [120 mM
NaH
#
PO
%
(pH 7.4)}1 mM MgCl
#
}1 mM EGTA}1 mM dithio-
threitol}20% glycerol and 40 mM octyl glucoside] and then
centrifuged at 18000 rev.}min (20000 g) for 40 min at 4 °C. The
resulting pellets were used as the membrane fraction.
Measurement of O2−d release by neutrophils
Neutrophils (0.5¬10' cells}ml) were added to paired cuvettes
containing 80 lM cytochrome c in KRB with a final assay
volume of 1 ml. O
#
−d was measured by monitoring the superoxide
dismutase-inhibitable reduction of cytochrome c at 550 nm, at
37 °C, using a diode-array double-beam spectrophotometer
(Hewlett Packard) [27]. O
#
−d production was stimulated by
different concentrations of the Ru–PDTA complex or 100 nM
mezerein. O
#
−d generation was calculated by using a molar
absorption coefficient of 21.1 mM−"[cm−".
Electrophoresis, immunoblotting and detection by enhanced
chemilumiscence
Membrane and cytosolic fractions were subjected to SDS}PAGE
on 10% polyacrylamide gels using the Laemmli buffer system
[28]. Separated proteins were transferred on to a nitrocellulose
membrane, which was blocked with 5% defatted milk. The mem-
brane was incubated with a mixture of partially purified
rabbit antibodies raised against p47phox and p67phox and finally
detected with horseradish peroxidase conjugated with goat anti-
rabbit IgG (1:5000 final dilution). The bound secondary antibody
was detected by enhanced chemiluminescence. Briefly, mem-
branes were incubated for 1 min in 10 ml of fresh luminescence
reagent solution, composed of 10 mM HCl}Tris, pH 8.5,
2.25 mM luminol, 0.015% (v}v) H
#
O
#
and 0.45 mM 4-
iodophenol, the latter acting as enhancer of the chemilumi-
nescence reaction [29]. These concentrations of luminol, H
#
O
#
and 4-iodophenol had been determined to be optimal for
maximum light production (M. Carballo, G. Marquez and
F. Sobrino, unpublished work). Luminol and 4-iodophenol were
freshly prepared in 10 ml of 10 mM Tris}HCl, pH 8.5. Luminol
was previously dissolved in 50 ll of 1 M NaOH. The use of
DMSO as solvent should be avoided since, under alkaline-
DMSO conditions, luminol autoxidizes with emission of intense
luminiscence [30]. After 1 min of incubation the membranes were
placed on a filter paper, covered with Saran wrap (‘clingfilm’)
and exposed to X-ray films (X-OMAT; Kodak) in the dark for
1–5 min.
Analysis of protein tyrosine phosphorylation
Neutrophils (5¬10' cells) in 0.5 ml of KRB were pretreated with
different concentrations of the Ru–PDTA complex. The reaction
was terminated at 20 min by centrifugation and aspiration of the
reaction medium. A volume (75 ll) of sample buffer [28] con-
taining 125 mM Tris}HCl (pH 6.8)}2% SDS}5% glycerol}5%
mercaptoethanol}0.003% Bromophenol Blue was added to the
pellet, and the samples were boiled for 5 min. The cell lysates
were resolved by SDS}10%-PAGE. Separated proteins were
electrotransferred to a nitrocellulose membrane. After blocking
with 3% BSA}1 mM PMSF}5 lg}ml aprotinin in TBST
[150 mM NaCl}50 mM Tris}HCl (pH 7.5)}0.1% Tween 20] the
membrane was incubated with anti-phosphotyrosine antibody
(PY20) (1:2000 final dilution). Bound antibodies were detected
by luminol enhanced chemiluminescence, as indicated above.
Protein concentrations were analysed as previously described
[31].
Measurement of intracellular Ca2+
Intracellular Ca#+ was analysed as described in [25]. Briefly,
neutrophils were incubated in a medium (Ca#+ medium) com-
posed of 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl, 1 mM
CaCl
#
, 20 mM Hepes at pH 7.4, at a concentration of 10(
cells}ml at 37 °C for 45 min in the presence of 2 lM Fura-2
acetoxymethyl ester and 2.5 mM probenecid. The excess of the
dye was then washed away, and the neutrophils were kept in the
same medium. Batches of 10( cells were resuspended in 0.6 ml of
Ca#+ medium at 37 °C, and the Ru–PDTA complex was added to
the cellular suspension. Fura-2 fluorescence (k
excitation
at 340 nm
and k
emission
at 500 nm) was recorded on a Perkin–Elmer LS-5
spectrofluorimeter. Ca#+ was calibrated using a value of 224 for
the K
d
of Fura-2.
RESULTS
Stimulation of the respiratory burst by the Ru–PDTA complex
The tumour promoter PMA has been described as the most
active stimulator of the respiratory burst [32]. In preliminary
experiments, human neutrophils were incubated with PMA and
the Ru–PDTA complex. It was found that the complex did not
alter a PMA-dependent respiratory burst (results not shown).
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Figure 1 Absorption measurement showing the reduction of cytochrome c
after neutrophil activation by the Ru–PDTA complex
Neutrophils (0.5¬106 cells/ml) were incubated with 10 lM (a), 25 lM (b), 50 lM (c) and
100 lM (d) for the indicated times. Data are representative of three independent experiments.
The dose-dependence of O2−d (¯ O2
.−) production is illustrated in the inset.
However, when the Ru–PDTA complex was added alone to cell
suspensions, a clear production of O
#
−d was found (Figure 1).
Successive additions of the Ru–PDTA induced a rapid stimula-
tion of O
#
−d production by neutrophils which seemed to be sus-
tained after 10 min of incubation. This O
#
−d production was
dependent upon the Ru–PDTA complex concentration with an
apparent k
!.&
of approx. 25 lM. (Figure 1, insert). It was verified
that some preparations of Ru–PDTA complex, in the absence of
cells, produced a slight decrease in cytochrome c, which oscillates
between 8 and 18% of the total change of absorbance, measured
when Ru–PDTA complex was added to cells. That unspecific
change of absorbance was substracted from experimental values
to obtain the specific Ru–PDTA-dependent O
#
−d production.
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Figure 2 Kinetics of production stimulated by the Ru–PDTA complex, RuCl3
and PDTA by human neutrophils
Neutrophils (0.5¬106 cells/ml) were incubated with 25 lM (+) or 50 lM (_) of the
Ru–PDTA complex, and 25 lM RuCl3 (D) or 25 lM PDTA (E). Values are means³S.E.M.
for three independent experiments.
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Figure 3 Effect of DPI and staurosporine on the Ru–PDTA-complex-
induced (O2−d) production by neutrophils
Neutrophils (0.5¬106 cells/ml) were incubated with 100 lM Ru–PDTA complex in the
absence (_) or in the presence of 10 lM DPI (+) or 1 lM staurosporine (U) for 10 min
at 37 °C. Data are means³S.E.M. for three independent experiments performed in duplicate.
Also, when Ru–PDTA complex was added to inactivated cells
(e.g. by heat), it had not effect. Further experiments were then
designed to assesswhether the stimulatory effect of theRu–PDTA
complex was due to the Ru–PDTA molecule itself or was due to
one or more of its constituents (e.g. Ru
$
Cl, PDTA). Figure 2
shows that only the Ru–PDTA complex had the capacity to
stimulate O
#
−d production, since neither RuCl
$
nor PDTA at
25 lM had any effect. Concentrations of the constituents higher
than 25 lM had no effect (results not shown). We then analysed
the specifity of Ru–PDTA-dependent O
#
−d production. Figure 3
illustrates that diphenylene iodonium (DPI), a well-known in-
hibitor of NADPH oxidase [33], decreased O
#
−d production by
approx. 25%. DPI at doses higher than 10 lM produced further
inhibition, but this never reached 100%. Previous data with
protein kinase inhibitors have demonstrated that NADPH oxi-
dase activation is mediated by protein phosphorylation [34,35].
The presence of 1 lM staurosporine produced a complete
inhibiton of Ru–PDTA-dependent formation O
#
−d (Figure 3).
The lower inhibition observed with DPI may be interpreted in
terms of previous findings, which indicate the necessity of
reducing conditions for inhibition of O
#
−d production by DPI
[36]. Since the Ru–PDTA complex forms an oxidant environment
[37], this may explain the decreased inhibitory capacity of DPI.
The response to the Ru–PDTA complex was not altered by
pertussis-toxin pretreatment, indicating that the involvement of
G
i
-type guanine-nucleotide-regulatory protein was unlikely.
Since pertussis toxin produces an activation of adenyl cyclase,
the effect of dibutyryl cyclic AMP was also investigated (results
not shown). In agreement with the observations with pertussis
toxin, cyclic AMP did not alter the response to the Ru–PDTA
complex. Previously [38] it was shown that cyclic AMP or agents
that elevate intracellular levels of cyclic AMP decrease O
#
−d
production [38]. However, it has been shown recently that cyclic
AMP treatment does not alter PMA-dependent O
#
−d production
in neutrophil-like HL-60 cells [39].
Translocation of NADPH oxidase subunits and phosphorylation on
tyrosine residues induced by the Ru–PDTA complex
Studies performed with neutrophils treated PMA and other
stimuli have shown that translocation of cytosolic p47phox and
p67phox to the plasma membrane is an essential process for the
562 M. Carballo and others
Figure 4 Effect of the Ru–PDTA complex on the translocation of p47phox
(p47) and p67phox (p67) from cytosol to the membrane
(A) Neutrophils (5¬106 cells/ml) were incubated with 25 and 50 lM Ru–PDTA complex for
20 min at 37 °C. Cytosolic and membrane fractions were separated and electrotransferred as
indicated in the Experimental section. The nitrocellulose membrane was then probed with anti-
p47phox and anti-p67phox antisera and proteins were revealed with luminol-enhanced chem-
iluminiscence. (B) Neutrophils were exposed to the Ru–PDTA (50 lM) for the indicated times,
and then analysed for p47phox and p67phox as indicated in the Experimental section. This Figure
is representative of three independent experiments.
activation of the NADPH oxidase ([40–42] ; for a review, see
[19]). In order to compare the translocation from cytosol to the
membrane of cytosolic proteins p47phox and p67phox, cytosolic
and membrane fractions from resting neutrophils or those
stimulated with the Ru–PDTA complex were subjected to
electrophoresis and immunoblotted with specific anti-p47phox
and anti-p67phox polyclonal antibodies. The results are shown in
Figures 4(A) and 4(B). Figure 4(A) shows that, with 25 lM of
the Ru–PDTA complex, there was a clear translocation of both
proteins from the cytosol to the plasma membrane after 20 min
and that this translocation was more pronounced with 50 lM
Ru–PDTA. In our hands p47phox was always readily detected
using the polyclonal antisera. By contrast, detection of p67phox,
particularly in plasma-membrane preparations, was less reliable.
This could be explained by the recent finding of Heyworth et al.
[43] that p67phox is located in the Triton X-100-insoluble fraction.
The kinetics of the translocation are shown in Figure 4(B). At
1 min after treatment with the Ru–PDTA complex, p47phox was
clearly detectable in the plasma membrane, whereas in cytosolic
fractions the opposite was observed. This translocation seemed
to be completed after 25 min, since no cytosolic p47phox was
detected at this time. The p67phox protein showed similar kinetics
of disappearance from the cytosol, but was barely detectable in
the plasma-membrane fraction.
It is well established that activation of NADPH oxidase by
different stimulants is accomplished by tyrosine phosphorylation
of several cytosolic proteins [44–46]. The next experiments were
therefore designed to assess whether the Ru–PDTA complex
produced a similar effect. Figure 5 shows that the Ru–PDTA
complex induced tyrosine phosphorylation of 40, 57, 66, 75, 100,
and 120 kDa proteins in a dose-dependent manner. It is note-
worthy that, in these last-mentioned experiments, the cytosolic
and membrane fractions were processed together. A similar
Figure 5 Tyrosine phosphorylation induced by the Ru–PDTA complex and
analysed by anti-phosphotyrosine immunoblotting
Neutrophils (5¬106 cells/ml) were pretreated for 20 min without complex (0 lM) or in the
presence of 25, 50 or 100 lM of Ru–PDTA complex. Phosphotyrosine was detected using a
luminol-enhanced chemiluminescence method. Arrows indicate molecular masses calculated
from the positions of the molecular-mass standards. This Figure is representative of three
independent experiments.
Figure 6 Dose-dependent effect of the Ru–PDTA on cytosolic free Ca2+
(Ca++)
The Ru–PDTA complex was added as follows : 2 lM (a), 5 lM (b) and 25 lM (c). The mean
change in peak value of [Ca2+]i at 25 lM of Ru–PDTA complex was (means³S.E.M.,
n ¯ 3) 164³6 nM. The Ca2+ concentration in resting cells was 91³4 nM. The results shown
are representative of three experiments.
pattern of phosphorylation was previously observed in neutro-
phils incubated with different stimuli [43–46]. When cells were
stimulated with Ru–PDTA complex in the presence of stauro-
sporine (1 lM), a diminished protein phosphorylation was
detected (results not shown). This fact agrees with previous
observations in human neutrophils [34].
Effect of the Ru–PDTA complex on Ca2+ levels
Ca#+ appears to play a role as a second messenger in the
neutrophil activation sequence, just as it does in other systems,
and the relative roles of intra- and extra-cellular calcium have
been assessed [47]. A rapid increase in cytosolic Ca#+ has been
demonstrated in neutrophils in response to a variety of stimuli
[48]. Figure 6 shows that the Ru–PDTA complex increased
intracellular Ca#+ in a dose-dependent manner and, at 5 lM Ru–
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PDTA complex, a clear effect was detectable. At 25 lM
Ru–PDTA complex a rapid onset of intracellular Ca#+ levels was
detected. This observation suggests a relationship between the
increased Ca#+ levels and the activation of the oxidase. However,
this classical Ca#+-dependent signalling pathway has been dis-
cussed in terms of different data (see [19] for a review), which
have demonstrated the possibility, under appropiate circum-
stances, of a Ca#+-independent oxidase activation. Also the effect
of Ru–PDTA was analysed in the presence of staurosporine
(1 lM). In this case staurosporine had no effect (results not
shown). The results obtained with staurosporine on Ca#+ levels
and phosphorylation on protein provided further evidence that
different signal-transduction processes are involved in Ru–
PDTA-dependent neutrophil activation.
In order to study the specific effect of Ru–PDTA complex on
neutrophils, other non-phagocytic cells (e.g. blood T-cell lym-
phocytes) were analysed. In the presence of Ru–PDTA complex,
no production of O
#
−d was detected in these cells. However,
Ru–PDTA complex was able to increase intracellular Ca#+ and
phosphorylation of proteins (results not shown), as it did in
neutrophils.
DISCUSSION
We have presented evidence that a novel complex, derived from
Ru$+ and a chelanting agent, PDTA, was able to stimulate O
#
−d
production by human neutrophils. This stimulation was specific
for the complex, since the individual constituents had no effect.
Several lines of evidence suggest that the complex acts as a true
stimulator of NADPH oxidase. First, the mechanism of ac-
tivation seems to be associated with the translocation of cytosolic
proteins, p47phox and p67phox, from cytosol to the plasma mem-
brane, since the assembly of the NADPH oxidase components is
a well-established phenomenon for other defined stimulators of
the enzyme [40–42]. The critical functional importance of these
two proteins was established by studies of a subset of chronic-
granulomatous-disease patients, who exhibit autosomal inherit-
ance, normal membrane content of cytochrome b
&&)
and a defect
localized to the cytosol in a cell-free oxidase system. Secondly,
the overall inhibition by staurosporine of the Ru–PDTA-
complex-dependent activation of NADPH oxidase suggests the
participation of protein kinase C, in a manner similar to other
stimuli. Also, a partial unresponsiveness of the Ru–PDTA
complex to DPI inhibition was detected, which could be due to
the requirement for a reduced environment for DPI activity, as
suggested by other authors [36]. Thirdly, the Ru–PDTA complex
elicited phosphorylation at tyrosine residues on several proteins
(Figure 5), with a phosphorylation pattern very similar to that
described previously [43–46]. In addition, the short time required
to produce a measurable response to the Ru–PDTA (Figure 1)
suggests that non-specific or cytotoxic effects are unlikely. The
stimulation of the respiratory burst elicited by the Ru–PDTA
complex seems to be independent of cyclic AMP levels, since
neither dibutyryl cyclic AMP nor pertussis toxin (which increases
cyclic AMP levels) altered the O
#
−d production.
Our present findings on the stimulation of the respiratory
burst by the Ru–PDTA complex provides a hypothetical model
to explain the antitumour properties of the compound. Evidence
based on structural studies indicates that phagocytic cells in-
filtrate tumour nodes, and this defence mechanism has been
observed in different tumour types [23,49]. Conversely, the
administration of agents that induce macrophage disruption or
dysfunction has been reported to increase host susceptibility to
neoplasia [50]. Also tumour rejection elicited by interleukin-4
[23] or interleukin-13 [49], delivered to the site of the tumour, is
the result of direct membrane and cytoplasmic damage to tumour
cells by eosinophils, neutrophils and macrophages that deeply
penetrate the proliferating tumour mass. Thus the death of
tumour cells elicited by the Ru–PDTA complex could be
interpreted as having been caused by the infiltrating neutrophils
(and other phagocytic cells). These cells, located near to tumour
nodes, are activated the by the Ru–PDTA complex to produce
an increased level of free radicals (e.g. O
#
−d), thereby providing
damage in the proximal tumour cells. Previously it has been
shown that another antineoplasic agent, a muramyl dipeptide
analogue, enhances killing activity on tumour cells and the
synthesis of O
#
−d by neutrophils [51]. Although the O
#
−d and
other reactive oxygen intermediates have traditionally been
viewed primarily as potent microbicidal agents synthesized by
phagocytic cells [52], the complexity of the phenomenon it is now
well recognized. The specifity of an oxygen-free radical-mediated
response is likely to depend on the activation status of individual
cells, as well as interference by, and integration with, other
possible concomitant signalling events [53].
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